We exist to bring meaningful medicines to patients quickly & safely.
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has a late-stage investigational pipeline including Acoramidis for ATTRv, BBP-418 for LGMD2I/R9, Encaleret for ADH1 and hypoparathyroidism, Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan Disease.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account